AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections

艾滋病毒及相关感染治疗研究艾滋病临床试验小组

• 批准号: 10493539
• 负责人: Judith S. Currier
• 金额: $ 1000万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2023-05-02
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10493539
• 关键词: AIDS clinical trial group; AIDS/HIV problem; Address; Affect; Aging; Anti-Retroviral Agents; Antiviral Agents; Area; Behavioral; Biological Markers; Blood; California; Cardiovascular system; Clinical; Clinical Research; Clinical Trials; Collaborations; Communication; Conduct Clinical Trials; Development; Disease; Disease remission; Drug resistance in tuberculosis; Epidemic; Evaluation; Funding; Goals; HIV; HIV Infections; HIV/TB; Health; Hepatitis B; Hepatitis B Virus; Immune; Immunologics; Industry Collaboration; Infection; Infrastructure; International; Intervention; Knowledge; Laboratories; Leadership; Los Angeles; Maintenance; Mental Health; Metabolic; Morbidity - disease rate; Multidrug-Resistant Tuberculosis; Neurologic; Obesity; Occupational activity of managing finances; Persons; Phase; Population; Prevention; Prevention and Treatment of Opportunistic Infection; Protocols documentation; Publishing; Regimen; Research; Research Personnel; Resources; Risk; Science; Specimen; System; Testing; Therapeutic; Therapeutic Intervention; Tissues; Training; Tuberculosis; Universities; Virus Diseases; active method; acute infection; antiretroviral therapy; burden of illness; chronic infection; collaboratory; community engagement; community involvement; comorbidity; comparative efficacy; data management; design; drug-sensitive; efficacy trial; improved; innovation; mortality; multidisciplinary; neutralizing antibody; novel; operation; prevent; protocol development; social; statistics; therapeutic vaccine; treatment guidelines

Project Summary The AIDS Clinical Trials Group (ACTG) has been at the forefront of clinical research to advance HIV therapeutics and improve the health of people living with HIV/AIDS for 30 years. Rigorous scientific research conducted by the ACTG has laid the cornerstones for current HIV treatment guidelines. In this application for the competitive renewal of the ACTG we propose a transformative research agenda that draws on an international consortium of leading clinical and laboratory HIV investigators in collaboration with a world-class Statistics and Data Management Center to design and conduct innovative interventional clinical trials that will significantly reduce the global burden of disease due to HIV, TB and hepatitis B. The Leadership and Operations Center (LOC) provides scientific leadership and fiscal and organizational management of the ACTG. The ACTG Executive Committee (AEC) will serve as the overarching governing body of the network. The AEC is guided by an Executive Management Committee that includes the Network Chairs, Chief Quality Officer and the Chairs of the Laboratory and Statistical and Data Management Centers. Transformative Science Groups will oversee the development and execution of the ACTG research agenda, which will be coordinated and prioritized by the Scientific Agenda Steering Committee (SASC). Protocol development, implementation, training and network evaluation will be facilitated by the Network Clinical Core at Social & Scientific Systems, Inc. The LOC financial management group (Admin Core) at the University of California, Los Angeles will oversee resource management and protocol fund distribution at the direction of the AEC. The LOC will assure the engagement of Community in all aspects of the ACTG, and will coordinate communication between all three components of the network. Specific aims of this proposal include: 1) Identify interventions to reduce HIV reservoirs and control HIV replication in the absence of ART; 2) Test novel and durable interventions targeting HIV infection; 3) Improve the treatment and prevention of drug sensitive and drug resistant tuberculosis; 4) Prevent or improve the treatment of HIV-related non-infectious co-morbidities and evaluate strategies to cure hepatitis B virus infection in people with and without HIV.

项目摘要 艾滋病临床试验组（ACTG）一直处于临床研究的最前沿，以促进HIV 治疗和改善艾滋病毒/艾滋病患者的健康30年。严格的科学研究 由ACTG进行的为当前的HIV治疗指南奠定了基石。在此申请中 ACTG的竞争更新我们提出了一个变革性研究议程，该议程借鉴了 领先的临床和实验室艾滋病毒研究者国际联盟与世界一流的合作 统计和数据管理中心设计和进行创新的介入临床试验 大大减轻了由于艾滋病毒，结核病和肝炎引起的全球疾病负担。 领导力和运营中心（LOC）提供科学领导力以及财政和组织 ACTG的管理。 ACTG执行委员会（AEC）将作为总体管理 网络主体。 AEC由包括网络在内的执行管理委员会指导 主席，首席质量官和实验室，统计和数据管理中心的椅子。 变革性科学小组将监督ACTG研究议程的发展和执行， 这将由科学议程指导委员会（SASC）协调并优先考虑。协议 网络临床核心将促进开发，实施，培训和网络评估 社会与科学系统公司 加利福尼亚州，洛杉矶将监督资源管理和协议基金分配 AEC。 LOC将确保社区在ACTG的各个方面的参与，并将协调 网络所有三个组成部分之间的通信。该提案的具体目的包括：1）确定 在没有艺术的情况下减少艾滋病毒储量和控制艾滋病毒复制的干预措施； 2）测试小说和 针对艾滋病毒感染的持久干预措施； 3）改善对药物敏感和药物的治疗和预防 抗性结核病； 4）防止或改善与HIV相关的非感染合并症和 评估治疗艾滋病毒和没有艾滋病毒的患者的丙型肝炎病毒感染的策略。